PARIS – A 30-day analysis of the EMPOWER CAD trial demonstrates that the Shockwave coronary intravascular lithotripsy (IVL) device is effective in the treatment of women with coronary artery disease (CAD) and calcified lesions.
Using intravascular lithotripsy as a preparation for percutaneous coronary intervention (PCI) on severely calcified lesions reduces procedural and target vessel failures at 1 year without increasing risk, according to the international BALI trial — the first to support routine lithotripsy use for these patients.
PARIS – In patients with ST-segment myocardial infarction (STEMI) and left ventricular (LV)-failure cardiogenic shock, immediate multivessel percutaneous coronary intervention (PCI) is associated with reduced mortality at 6 months, a substudy of the DanGer shock trial shows.
Researchers reveal that patients with bicuspid aortic valves may have a higher chance of successful repeat transcatheter aortic valve replacement (redo-TAVR) compared to those with tricuspid valves.
New insights from a multicenter European study demonstrate that intravascular ultrasound (IVUS) can safely and effectively guide decisions to avoid unnecessary coronary stenting during transcatheter aortic valve replacement (TAVR).
Japanese researchers suggest that complex cases of chronic total occlusion (CTO) with bifurcation at the distal cap can be treated successfully using refined strategies, especially with use of the retrograde approach.
The association between social determinants of health (SDOH) and increased rates of death due to cardiovascular disease (CVD) is mediated by behavioral and clinical risk factors, a new survey study shows.
Calprotectin may be a biomarker for atherosclerotic cardiovascular disease (ASCVD), a new study shows.
The degree of ischemia detected on dobutamine stress echocardiography (DSE) strongly predicts the efficacy of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD), according to a new analysis from the ORBITA-2 trial.
King and I | S6 E1 | Quality of Life Measures in Asymptomatic TAVR Patients & Device Approvals
Bailey G. Salimes, CRTonline.org
Will Chu, CRTonline.org
Natalie Morrison, CRTonline.org
Nathan Gray, CRTonline.org
Michael Mahmoudi, MD - C Terkelsen, et al.; Lancet 2025; 405:1362-1372
Michael Mahmoudi, MD - X Hu, et al.; Lancet 2025; 405:1491-1504
Michael Mahmoudi, MD - W Fearon, et al.; Lancet 2025; 405:1481-1490
Michael Mahmoudi, MD - S Nissen, et al.; NEJM 2025 Online
BUSINESS WIRE
HighLife
PRNewswire
GLOBE NEWSWIRE
Do you think there is a role for embolic protection devices in patients undergoing TAVR?
Yes
No
Only on a subset of patients
Dimitrios Strepkos, Michaella Alexandrou, Deniz Mutlu, Pedro E.P. Carvalho, Ozgur S. Ser, Jaskanwal Deep Singh Sara, Oleg Krestyaninov, Dimitri Khelimskii, Barkin Kultursay, Ali Karagoz, Ufuk Yildirim, Korhan Soylu, Mahmut Uluganyan, Olga Mastrodemos, Bavana V. Rangan, Sandeep Jalli, Konstantinos Voudris, M. Nicholas Burke, Yader Sandoval and Emmanouil S. Brilakis
Luca Paolucci, Alejandro Diego, Alfonso Jurado, Ignacio Amat, Rocco Stio, Laura Novelli, Jorge Sanz, Anna Laffond, Mattia Basile, Mateo Giordano, Francesco de Felice, Adrián Jerónimo, Giulia Nardi, Javier Moreiras, Gabriele Gasparini, Nieves Gonzalo, Javier Escaned and Pablo Salinas
Artur Dziewierz
Sraman Chatterjee, Joris Ooms, Marjo de Ronde, Stefan van Gorsel, Antonio Maarten Mattace-Raso, Jeannette Goudzwaard, Francesco Mattace-Raso, Isabella Kardys, Rutger-Jan Nuis, Joost Daemen and Nicolas Van Mieghem
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details